Ulcerative Colitis: The Role of Targeted Therapy

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that has a severe impact on patient physical and psychosocial health and quality of life. Because it is a progressive disease, early and effective treatment is important to control gastrointestinal inflammation and prevent long-term damage to the GI tract. While TNF inhibitors have been the mainstay of treatment for many years, more recently several novel targeted therapies have been approved for moderate-to-severe UC. These agents target the underlying mechanisms of UC pathogenesis and result in long-term clinical remission and improvement of UC symptoms for many patients.

This activity, Ulcerative Colitis: The Role of Targeted Therapy, will provide gastroenterologists with information on the immunopathology of UC, the efficacy and safety of more recently approved targeted therapies, and the latest guidelines for management of patients with UC.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc